CN110577464A - Preparation method of resveratrol - Google Patents
Preparation method of resveratrol Download PDFInfo
- Publication number
- CN110577464A CN110577464A CN201810632852.0A CN201810632852A CN110577464A CN 110577464 A CN110577464 A CN 110577464A CN 201810632852 A CN201810632852 A CN 201810632852A CN 110577464 A CN110577464 A CN 110577464A
- Authority
- CN
- China
- Prior art keywords
- compound
- resveratrol
- raw materials
- taking
- namely
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 title claims abstract description 46
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 title claims abstract description 45
- 235000021283 resveratrol Nutrition 0.000 title claims abstract description 45
- 229940016667 resveratrol Drugs 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 16
- 238000006243 chemical reaction Methods 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 14
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 14
- -1 3, 5-dimethoxy benzyl Chemical group 0.000 claims abstract description 12
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 12
- 150000001875 compounds Chemical class 0.000 claims abstract description 12
- BDZBKCUKTQZUTL-UHFFFAOYSA-N triethyl phosphite Chemical compound CCOP(OCC)OCC BDZBKCUKTQZUTL-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229940126062 Compound A Drugs 0.000 claims abstract description 6
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims abstract description 6
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 claims abstract description 6
- AUDBREYGQOXIFT-UHFFFAOYSA-N (3,5-dimethoxyphenyl)methanol Chemical compound COC1=CC(CO)=CC(OC)=C1 AUDBREYGQOXIFT-UHFFFAOYSA-N 0.000 claims abstract description 5
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 claims abstract description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229910000104 sodium hydride Inorganic materials 0.000 claims abstract description 4
- 239000012312 sodium hydride Substances 0.000 claims abstract description 4
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 claims abstract 5
- 230000002194 synthesizing effect Effects 0.000 claims abstract 4
- GDHNBPHYVRHYCC-SNAWJCMRSA-N 1,3-dimethoxy-5-[(e)-2-(4-methoxyphenyl)ethenyl]benzene Chemical compound C1=CC(OC)=CC=C1\C=C\C1=CC(OC)=CC(OC)=C1 GDHNBPHYVRHYCC-SNAWJCMRSA-N 0.000 claims abstract 2
- BTHIGJGJAPYFSJ-UHFFFAOYSA-N 1-(bromomethyl)-3,5-dimethoxybenzene Chemical compound COC1=CC(CBr)=CC(OC)=C1 BTHIGJGJAPYFSJ-UHFFFAOYSA-N 0.000 claims abstract 2
- 229910019142 PO4 Inorganic materials 0.000 claims abstract 2
- 239000010452 phosphate Substances 0.000 claims abstract 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000005457 ice water Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 4
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 2
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 2
- 238000001953 recrystallisation Methods 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 5
- 239000000543 intermediate Substances 0.000 abstract description 3
- 230000002349 favourable effect Effects 0.000 abstract description 2
- 238000009776 industrial production Methods 0.000 abstract description 2
- 206010028980 Neoplasm Diseases 0.000 description 6
- UYEMGAFJOZZIFP-UHFFFAOYSA-N 3,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC(O)=C1 UYEMGAFJOZZIFP-UHFFFAOYSA-N 0.000 description 4
- 238000007341 Heck reaction Methods 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 238000007239 Wittig reaction Methods 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000006546 Horner-Wadsworth-Emmons reaction Methods 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- VFZRZRDOXPRTSC-UHFFFAOYSA-N 3,5-Dimethoxybenzaldehyde Chemical compound COC1=CC(OC)=CC(C=O)=C1 VFZRZRDOXPRTSC-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 238000003684 Perkin reaction Methods 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 102000011990 Sirtuin Human genes 0.000 description 2
- 108050002485 Sirtuin Proteins 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000007697 cis-trans-isomerization reaction Methods 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 238000005935 nucleophilic addition reaction Methods 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 150000008301 phosphite esters Chemical class 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical group C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- CMQGCWMEXQRWSS-MDZDMXLPSA-N 1,2,3-trimethoxy-5-[(e)-2-phenylethenyl]benzene Chemical compound COC1=C(OC)C(OC)=CC(\C=C\C=2C=CC=CC=2)=C1 CMQGCWMEXQRWSS-MDZDMXLPSA-N 0.000 description 1
- VCZQMZKFNJPYBI-UHFFFAOYSA-N 2-(4-propan-2-yloxyphenyl)acetic acid Chemical compound CC(C)OC1=CC=C(CC(O)=O)C=C1 VCZQMZKFNJPYBI-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- RVJSOGIYAICWMA-UHFFFAOYSA-N 3,5-di(propan-2-yloxy)benzaldehyde Chemical compound CC(C)OC1=CC(OC(C)C)=CC(C=O)=C1 RVJSOGIYAICWMA-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- PYIXHKGTJKCVBJ-UHFFFAOYSA-N Astraciceran Natural products C1OC2=CC(O)=CC=C2CC1C1=CC(OCO2)=C2C=C1OC PYIXHKGTJKCVBJ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- NDVRQFZUJRMKKP-UHFFFAOYSA-N Betavulgarin Natural products O=C1C=2C(OC)=C3OCOC3=CC=2OC=C1C1=CC=CC=C1O NDVRQFZUJRMKKP-UHFFFAOYSA-N 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003964 Histone deacetylase Human genes 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- QPJVMBTYPHYUOC-UHFFFAOYSA-N Methyl benzoate Natural products COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- IHPVFYLOGNNZLA-UHFFFAOYSA-N Phytoalexin Natural products COC1=CC=CC=C1C1OC(C=C2C(OCO2)=C2OC)=C2C(=O)C1 IHPVFYLOGNNZLA-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000003005 anti-senility effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 150000003934 aromatic aldehydes Chemical class 0.000 description 1
- 125000005251 aryl acyl group Chemical group 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 238000006254 arylation reaction Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000012627 chemopreventive agent Substances 0.000 description 1
- 229940124443 chemopreventive agent Drugs 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001335 demethylating effect Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 238000007344 nucleophilic reaction Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- AUONHKJOIZSQGR-UHFFFAOYSA-N oxophosphane Chemical compound P=O AUONHKJOIZSQGR-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000280 phytoalexin Substances 0.000 description 1
- 150000001857 phytoalexin derivatives Chemical class 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- AETSDHMVQHOYPB-UHFFFAOYSA-M sodium;4-methoxybenzoate Chemical compound [Na+].COC1=CC=C(C([O-])=O)C=C1 AETSDHMVQHOYPB-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000018991 trans-resveratrol Nutrition 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
- C07C37/001—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by modification in a side chain
- C07C37/002—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by modification in a side chain by transformation of a functional group, e.g. oxo, carboxyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
- C07C41/01—Preparation of ethers
- C07C41/18—Preparation of ethers by reactions not forming ether-oxygen bonds
- C07C41/22—Preparation of ethers by reactions not forming ether-oxygen bonds by introduction of halogens; by substitution of halogen atoms by other halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
- C07C41/01—Preparation of ethers
- C07C41/18—Preparation of ethers by reactions not forming ether-oxygen bonds
- C07C41/30—Preparation of ethers by reactions not forming ether-oxygen bonds by increasing the number of carbon atoms, e.g. by oligomerisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4056—Esters of arylalkanephosphonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4075—Esters with hydroxyalkyl compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
the invention belongs to the technical field of preparation of key intermediates of medicaments, and particularly relates to a preparation method of resveratrol. The synthesis preparation method of the resveratrol comprises the following steps: a. synthesizing 3, 5-dimethoxy benzyl bromide (compound A) by using 3, 5-dimethoxy benzyl alcohol and phosphorus tribromide as raw materials; b. taking a compound A, triethyl phosphite and tetrabutylammonium bromide as raw materials, and synthesizing to obtain 3, 5-dimethoxy benzyl diethyl phosphate (a compound B); c. taking a compound B, dimethyl diamide, sodium hydride and anisaldehyde as raw materials, and reacting to synthesize (E)3, 4', 5-trimethoxy stilbene (compound C); d. and (3) taking the compound C and pyridine hydrochloride as raw materials, and reacting and synthesizing to obtain the 3, 4, 5-trihydroxy-1, 2-stilbene, namely the resveratrol. The method has the characteristics of cheap and easily-obtained raw materials, mild reaction conditions, simple and convenient operation, high yield and low cost, and is favorable for industrial production.
Description
Technical Field
The invention belongs to the technical field of preparation of key intermediates of medicaments, and particularly relates to a preparation method of a medicament intermediate resveratrol which has the effects of resisting cancers, mutation, oxidation and free radicals, preventing cardiovascular and cerebrovascular diseases, resisting bacteria and inflammation and regulating an immune system.
Background
Resveratrol is a natural antioxidant, can reduce blood viscosity, inhibit platelet coagulation and vasodilatation, keep blood smooth, prevent cancer occurrence and development, and has effects of resisting atherosclerosis and coronary heart disease, ischemic heart disease, and hyperlipemia. The tumor inhibiting effect also has estrogen-like effect, and can be used for treating diseases such as breast cancer.
Resveratrol is a high-added-value natural product with good application prospect, and has various beneficial physiological activities of cancer prevention and resistance, blood fat reduction, platelet aggregation resistance, Sirtuins antisenility enzyme activation, antioxidation, free radical resistance, antianaphylaxis, antibiosis and antiphlogosis, osteoporosis resistance, skin care and whitening and the like. In recent years, a series of research reports and commendative articles about the bioactivity of resveratrol appear in world famous scientific journals including Science and Nature, and indicate that resveratrol can improve the survival rate of cells and prolong the life of organisms by activating Sirtuins enzyme and stabilizing DNA repetitive sequences. The resveratrol can also effectively resist central nerve ischemic injury, protect neurons in an ischemic area, reduce the infarction range, reduce delayed nerve cell apoptosis caused by ischemia reperfusion, improve limb movement dysfunction caused by cerebral ischemia and the like. The important biological activity and application value of resveratrol are widely concerned by the medical field, the industrial field, the news field and common people, and new pharmaceutical research categories led by resveratrol, such as protein deacetylase activator STACS, cancer chemopreventive agents and neuroprotective agents, become the thermoelectric and frontier fields of scientific research at present.
Resveratrol is mainly extracted from plants, but the application of resveratrol in the aspects of industrialization scale, medicine and functional food is limited due to the extremely low content of resveratrol. At the same time, the predation and destructive mining of resources is also extremely harmful to the ecological environment. Therefore, artificial synthesis of resveratrol has been attracting attention of researchers in various countries.
At present, the chemical synthesis of resveratrol mainly comprises 3 steps of formation of a stilbene skeleton, cis-trans isomerization and deprotection, wherein the key is the formation of the stilbene skeleton. The most studied chemical synthesis methods at present share class 4 classical methods.
Perkin reaction
the Perkin reaction is a reaction of aromatic aldehyde and acid anhydride in the presence of sodium carboxylate salt and potassium carboxylate salt of corresponding acid of the acid anhydride to produce beta-aromatic acrylic acid compound. In 1941, trans-3, 4, 5-trimethoxystilbene was obtained by first Perkin condensation of 3, 5-dimethoxybenzaldehyde and sodium p-methoxybenzoate by Spath et al, but it was not comparable to natural extraction because no crystals could be obtained after decarboxylation. However, Spath was not abandoned and they decarboxylated the product and placed in a mixture of methanol and hydrochloric acid, giving pure trans-crystals after 48 h. In 2003, the method of the Spath is improved by Solladie, 3, 5-diisopropoxybenzaldehyde and p-isopropoxyphenylacetic acid are used as raw materials for synthesis to obtain a product with a single cis-configuration, and the product is subjected to isomerization and protective group removal to obtain trans-structure resveratrol, wherein the total yield of the resveratrol is as high as 55.2%.
Wittig and Wittig-Horner reactions
The Wittig reaction is a reaction for forming a double bond commonly used in organic synthesis, wherein a Wittig reagent (phosphorus ylide) and carbonyl groups of aldehyde and ketone undergo a nucleophilic addition reaction to form new olefin and phosphine oxide. Reimann firstly takes 3, 5-bis (trimethylsiloxy) methyl benzoate as a raw material to prepare resveratrol through a Wittig reaction.
The Wittig-Horner reaction is an improvement on the Wittig reaction, and utilizes simple and easily-obtained phosphite ester to replace a phosphorus ylide reagent prepared from triphenylphosphine to react with aldehyde ketone to form double bonds. The method has mild conditions, simple and convenient operation, high yield and good stereoselectivity. Taking 3, 5-dihydroxy benzoic acid as a raw material, sequentially protecting hydroxyl, reducing, chlorinating and reacting with triethyl phosphite to generate 3, 5-dimethoxy benzyl diethyl phosphonate, then carrying out Wittig-Horner reaction with anisaldehyde, and removing protecting groups in pyridine hydrochloride to finally obtain resveratrol. Phosphite ester has poor atom economy, and expensive boron tribromide is used in the demethylation reaction, which seriously restricts the industrial implementation of the method.
Heck reaction
The Heck reaction is an olefin arylation and alkenylation coupling reaction of a palladium catalyst and has high trans-stereoselectivity. The Heck reaction condition is mild, the operation is simple, and the application in organic synthesis is very wide. 3, 5-dihydroxy benzoic acid is used as an initial raw material, aryl acyl chloride is used for replacing aryl halide to carry out Heck reaction, and the resveratrol is synthesized, wherein the total yield is as high as 53%. The method has simple steps, high selectivity and easy deprotection, but the palladium-containing complex used as the transition metal catalyst has high price and toxicity, and is not suitable for industrial mass production.
4. By condensation of carbanions with carbonyl compounds
The carbanion and carbonyl have nucleophilic addition reaction, and the obtained hydroxyl can form double bonds after elimination, so that the reaction is suitable for synthesis of resveratrol. The silicon derivative of 3, 5-dimethoxybenzyl alcohol is reacted with strong alkali to form benzyl carbanion which attacks the carbonyl group of anisaldehyde, and then the benzyl carbanion is dehydrated and demethylated to finally obtain single trans-resveratrol, wherein the total yield is 21%. The method has certain advantages in configuration selection, but the steps of the synthetic route are complicated, and the nucleophilic reaction yield is low.
The method has the defects of long route, low raw material economy, high cost, complex operation, poor trans-form selectivity, need of cis-trans isomerization, high demethylating reagent cost and the like, so that the continuous search of an efficient, simple and green resveratrol synthesis method has great significance.
In recent years, many scholars at home and abroad carry out more deep research on the bioactivity of resveratrol, and the resveratrol is found to be an important phytoalexin, can prevent the oxidation of low-density lipoprotein, has the effects of preventing and treating cardiovascular diseases, preventing cancer, resisting virus, resisting aging, regulating immunity and the like, and the American institute of natural medicine also finds that the resveratrol has the effect of resisting AIDS. At present, the global resveratrol market demands a lot, and the current production capacity is small, and the demand gap is large.
Disclosure of Invention
The invention aims to solve the technical problems of high cost, low synthesis efficiency, difficult separation and purification and difficult industrialized mass production in the prior art for preparing the resveratrol, and provides a novel method for preparing the resveratrol, which has the advantages of cheap and easily-obtained raw materials, mild reaction conditions, simple and convenient operation, high synthesis efficiency and favorable industrialized production.
Step one, in an organic solvent dichloromethane, 3, 5-dimethoxy benzyl alcohol compound (1) and pyridine and phosphorus tribromide are subjected to hydroxyl protection and bromination, and are concentrated and recrystallized to obtain a compound (2)
Reacting the two compounds (2) with triethyl phosphite and tetrabutylammonium bromide to obtain a compound (3)
Reacting the compound (3) with DMF, sodium hydride and anisaldehyde to obtain a compound (4)
Step four, reacting the compound (4) with pyridine hydrochloride for recrystallization reaction to obtain resveratrol
In the first step, 3, 5-dimethoxy benzyl alcohol reacts with pyridine in dichloromethane, phosphorus tribromide is dropwise added under ice bath, the reaction is carried out for three hours at room temperature, and water is dropwise added after the temperature is reduced to 0-5 ℃.
Step two, the reaction requires 160 ℃ for 8 hours
In the third step, anisaldehyde is added dropwise for one hour, the reaction is carried out for 6 hours at the temperature of 0 ℃, and an ice-water mixture is added.
And step four, reacting with pyridine hydrochloride for 50 minutes at 190 ℃, adding ice water, stirring, extracting with ethyl acetate, and recrystallizing with ethanol water to obtain resveratrol.
The invention has the advantages that: the preparation method of resveratrol provided by the invention has the advantages of cheap and easily available raw materials, mild reaction conditions, simple and convenient operation, high synthesis efficiency and high synthesis purity, is suitable for industrial production, and provides a new way for preparing resveratrol.
Detailed Description
The present invention will be further described with reference to the following examples. It should be understood that the examples are for illustrative purposes only and are not intended to limit the scope of the present invention.
The starting materials or reagents used in the examples are, unless otherwise specified, commercially available.
Adding 3, 5-dimethoxy benzyl alcohol 84g, dichloromethane 280ml and pyridine 1.7ml into a reaction bottle, dropwise adding phosphorus tribromide 29.3ml under ice bath, reacting for three hours at room temperature, cooling to 0-5 ℃, dropwise adding water 200ml, separating out a water layer, extracting with dichloromethane 100ml, concentrating and drying magnesium sulfate, adding methanol 200ml, and recrystallizing to obtain a compound A
80gA and 140ml triethyl phosphite 1.8g tetrabutylammonium bromide are added into a reaction flask for reaction at 160 ℃ for 8 hours, and the triethyl phosphite is recovered under reduced pressure to obtain a product B
Adding 68g of sodium hydride into all B and 400ml of DMF at-10 ℃, dropwise adding 46g of anisaldehyde (dropwise adding for one hour), reacting for 6 hours at 0 ℃, pouring into an ice-water mixture, precipitating a solid, filtering, drying at 45 ℃, and obtaining a product C after 2 hours.
Adding 69.3g of pyridine hydrochloride into 16.2g of C, reacting at 190 ℃ for 50 minutes, pouring into 200ml of ice water, stirring, extracting with 1L of ethyl acetate, layering, washing with water, drying with sodium sulfate, recovering ethyl acetate, and recrystallizing with ethanol water to obtain resveratrol.
Drawings
FIG. 1 is a scheme of synthesis of resveratrol
FIG. 2 is a reversed phase chromatogram of resveratrol.
Claims (5)
1. The synthesis preparation method of resveratrol comprises the following steps:
a. 3, 5-dimethoxy benzyl alcohol and phosphorus tribromide are used as raw materials to react and synthesize to obtain 3, 5-dimethoxy benzyl bromide, namely a compound A;
b. Taking a compound A, triethyl phosphite and tetrabutylammonium bromide as raw materials, and reacting to synthesize 3, 5-dimethoxy benzyl diethyl phosphate, namely a compound B;
c. Taking a compound B, dimethyl diamide, sodium hydride and anisaldehyde as raw materials to react and synthesize (E)3, 4', 5-trimethoxy stilbene, namely a compound C;
d. And (3) taking the compound C and pyridine hydrochloride as raw materials, and reacting and synthesizing to obtain the 3, 4, 5-trihydroxy-1, 2-stilbene, namely the resveratrol.
2. the method for preparing resveratrol according to claim 1, wherein in step a, phosphorus tribromide is added dropwise to dichloromethane, a mixture of 3, 5-dimethoxybenzyl alcohol and pyridine under ice bath conditions, the mixture is reacted for 3h at room temperature, the temperature is reduced to 0-5 ℃, 200mL of water is added, an aqueous layer is separated, extraction is carried out by dichloromethane, magnesium sulfate is concentrated and dried, and recrystallization is carried out by methanol to obtain the compound A.
3. The method for preparing resveratrol according to claim 1 wherein compound a, triethyl phosphite and tetrabutylammonium bromide are reacted to form compound B in step B, the temperature is controlled at 170 ℃ under the reaction conditions, the reaction time is 6-9h, and triethyl phosphite is recovered under reduced pressure.
4. The method of preparing resveratrol according to claim 1, wherein anisaldehyde is added dropwise in step c for 1 hour, then reacted at 0 ℃ for 5.5 to 6.5 hours, added with an ice water mixture, filtered and dried at 40 to 50 ℃.
5. the method for preparing resveratrol according to claim 1, wherein the compound C in step d is reacted with pyridine hydrochloride at 180-200 ℃ for 45-60min, ethyl acetate is stirred and extracted under ice bath, and ethanol water is recrystallized to obtain resveratrol.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810632852.0A CN110577464A (en) | 2018-06-09 | 2018-06-09 | Preparation method of resveratrol |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810632852.0A CN110577464A (en) | 2018-06-09 | 2018-06-09 | Preparation method of resveratrol |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110577464A true CN110577464A (en) | 2019-12-17 |
Family
ID=68809900
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810632852.0A Pending CN110577464A (en) | 2018-06-09 | 2018-06-09 | Preparation method of resveratrol |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110577464A (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101475451A (en) * | 2009-02-13 | 2009-07-08 | 南京师范大学 | Method for synthesizing trans-resveratrol |
CN102617302A (en) * | 2012-02-27 | 2012-08-01 | 浙江新赛科药业有限公司 | Process for synthesizing trimethoxyphenyl stilbene |
CN103570508A (en) * | 2013-11-01 | 2014-02-12 | 湖南科源生物制品有限公司 | Total synthesis method of trans-resveratrol |
-
2018
- 2018-06-09 CN CN201810632852.0A patent/CN110577464A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101475451A (en) * | 2009-02-13 | 2009-07-08 | 南京师范大学 | Method for synthesizing trans-resveratrol |
CN102617302A (en) * | 2012-02-27 | 2012-08-01 | 浙江新赛科药业有限公司 | Process for synthesizing trimethoxyphenyl stilbene |
CN103570508A (en) * | 2013-11-01 | 2014-02-12 | 湖南科源生物制品有限公司 | Total synthesis method of trans-resveratrol |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA3141590C (en) | Catalytic cannabinoid processes and precursors | |
CN109761867B (en) | Vitamin D production by using lanolin as raw material3Is a new method for industrialization | |
CN102653533B (en) | Total synthesis method of mangostin | |
CN108558627B (en) | Method for preparing 5-hydroxy-1-indanone | |
CN102050715B (en) | Preparation method of industrial musk tonalide | |
Baker et al. | Derived Steroids. I. Cholesteryl Ketones1 | |
CN107032972B (en) | Preparation method of Diels-Alder product with 2' -hydroxychalcone structure | |
CA1110272A (en) | 4-hydroxy phenylacetic acid | |
CN110577464A (en) | Preparation method of resveratrol | |
CN110845466B (en) | Oxacyclonadiene derivatives, pharmaceutical compositions thereof, process for their preparation and their use | |
CN1332929C (en) | One-pot-method for preparing caffeic acid ester derivants | |
Baldwin et al. | Complete kinetic analysis of the thermal stereomutations of (+)-(1S, 2S, 3R)-r-1-cyano-t-2-methyl-1, 2, t-3-trideuteriocyclopropane | |
CN110950746A (en) | Micro-continuous flow process for producing musk tonalide | |
CN103172499B (en) | Oxyresveratrol synthesis method | |
CA2288485A1 (en) | Preparation of trifluorobenzoic acids | |
CN111269094B (en) | Preparation method of 2-bromo-1, 3-dimethoxybenzene | |
Aoyama et al. | Synthesis of functionalized adamantanes from fluoroadamantanes | |
EP0650952B1 (en) | Process for 3,5-di-tert-butylsalicylaldehyde | |
CN111072625A (en) | Preparation method of 3, 4-methylenedioxyacetophenone | |
US7368593B1 (en) | Method of selective esterification | |
CN108203396B (en) | Synthesis of enkephalinase inhibitor | |
CN108689805B (en) | Preparation method of resveratrol | |
CN109665948A (en) | A method of ortho vanillin is prepared by raw material of catechol | |
CN103709092B (en) | The preparation method of Mitiglinide Calcium | |
JP4759722B2 (en) | Process for producing aromatic carboxylic acid ester having a substituent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20191217 |
|
WD01 | Invention patent application deemed withdrawn after publication |